Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C-Reference-Cited by-同舟云学术

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

Published:2008-04-24 Issue:5 Volume:47 Page:1453-1461
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Loustaud-Ratti Véronique,Alain Sophie,Rousseau Annick,Hubert Isabelle Fouchard,Sauvage François Ludovic,Marquet Pierre,Denis François,Lunel Françoise,Calès Paul,Lefebvre Annie,Fauchais Anne-Laure,Liozon Eric,Vidal Elisabeth

Funder

Centre Hospitalier Universitaire de Limoges

Roche, France

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.22217/fullpdf

Reference25 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. The clinical pharmacology of ribavirin;Glue;Semin Liver Dis,1999

4. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C;Jen;Ther Drug Monit,2000

5. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models;Jen;Clin Pharmacol Ther,2002

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#;Intensive Care Medicine;2020-05-07

2. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients;Pharmacological Research;2018-04

3. Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial;Journal of Interferon & Cytokine Research;2017-11

4. Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations;Digestive and Liver Disease;2017-06

5. Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin;Therapeutic Drug Monitoring;2016-12